Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2549
Peer-review started: December 27, 2022
First decision: January 20, 2023
Revised: February 2, 2023
Accepted: March 22, 2023
Article in press: March 22, 2023
Published online: April 16, 2023
Processing time: 100 Days and 6.9 Hours
Lichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common form of primary cutaneous amyloidosis. The treatment of LA has been considered to be difficult. LA may be associated with atopic dermatitis (AD), and in this setting, the treatment options may be more limited. Herein, we report four cases of LA associated with AD successfully treated by dupilumab.
In this article, we describe four cases of patients who presented with recurrent skin rash accompanied by severe generalized intractable pruritus, diagnosed with refractory LA coexisting with chronic AD. Previous treatments had not produced any apparent improvement. Thus, we administered dupilumab injection subcutaneously at a dose of 600 mg for the first time and 300 mg every 2 wk thereafter. Their lesions all markedly improved.
Dupilumab may be a new useful treatment for LA coexisting with AD.
Core Tip: Lichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common subtype of primary cutaneous amyloidosis characterized by deposition of amyloid protein on the skin without visceral involvement. The treatment of LA has been considered difficult, with high relapse rates. In this article, we present four cases of LA associated with atopic dermatitis (AD) treated with dupilumab who achieved remarkable results. Our observations suggested that dupilumab may shed light on the systematic treatment of refractory LA patients with AD.